Core Viewpoint - The board of directors of Heng Rui Medicine has announced a postponement of the board election, extending the terms of the current board members and senior management until February 1, 2026, to ensure governance stability and avoid disruptions in research and commercialization processes [1][7][16]. Group 1: Board and Management Changes - The current board of directors, including key executives such as Chairman Sun Piaoyang and President Dai Hongbin, will continue their roles until the new board is elected [3][12]. - The postponement of the board election may be influenced by factors such as strategic continuity, shareholder opinion coordination, and candidate selection [7][16]. - As of February 3, 2023, Heng Rui Medicine's A-share price was 57.47 yuan, with a market capitalization of 381.44 billion yuan, while its Hong Kong stock price was 67 HKD, with a market capitalization of 444.69 billion HKD [7][16]. Group 2: Financial Performance and Business Development - In the first three quarters of 2024 and 2025, Heng Rui Medicine reported revenues of 27.985 billion yuan and 23.188 billion yuan, representing year-on-year growth of 22.63% and 14.85%, respectively [8][17]. - The net profits for the same periods were 6.337 billion yuan and 5.751 billion yuan, with year-on-year increases of 47.28% and 24.50% [8][17]. - The company achieved significant revenue from its innovative drug business, with sales and licensing income of 9.561 billion yuan in the first half of 2025, accounting for 60.66% of total revenue [9][18]. Group 3: Market Position and Competitive Landscape - Despite strong growth, Heng Rui Medicine faces challenges from competitors, particularly in the innovative drug sector, where it must contend with similar products from other companies [10][21]. - The company’s overseas revenue was approximately 716 million yuan in 2024, constituting only 2.86% of total revenue, highlighting a significant gap compared to competitors like BeiGene, which had over 60% of its revenue from international markets [9][18]. - The oncology segment remains the largest revenue source for Heng Rui Medicine, generating approximately 14.587 billion yuan in 2024, with a gross margin of 92.57% [19][20].

Core Viewpoint - Yifan Pharmaceutical (002019) announced that the company and its controlling subsidiaries have not provided guarantees for units outside the scope of the consolidated financial statements, nor do they have overdue guarantees, litigation-related guarantee amounts, or losses due to judgments against guarantees [1] Group 1 - The company has not provided any guarantees for units outside the consolidated financial statements [1] - There are no overdue guarantees reported by the company [1] - The company has not incurred any losses due to judgments related to guarantees [1]

（文章来源：证券日报） 证券日报网讯 2月3日，贵研铂业在互动平台回答投资者提问时表示，公司铂抗癌药是仿制药，目前已 完成国家药监局注册申报用小试阶段工艺研究以及实验室公斤级别的放大试生产，后续将开展商业化批 量的试生产以及工艺验证工作。 ...

Core Viewpoint - Huadong Medicine (000963.SZ) announced that its wholly-owned subsidiary, Sino-American Huadong, received the Acceptance Notice from the National Medical Products Administration for the marketing application of ZORYVE (0.05% Roflumilast Cream), aimed at treating mild to moderate atopic dermatitis in patients aged 2 to 5 years [1] Group 1: Product Development - The drug is a collaborative innovation between Sino-American Huadong and Arcutis Biotherapeutics, Inc., with exclusive rights in Greater China and Southeast Asia [1] - Roflumilast cream offers safety advantages over traditional treatment methods and can be applied to all body parts with once-daily dosing, enhancing treatment adherence [1] Group 2: Market Positioning - The acceptance of the marketing application represents a significant milestone in the product development process, which will enhance the company's core competitiveness in the autoimmune skin treatment sector [1] - There are uncertainties regarding the drug review and approval timeline, approval outcomes, and future market competition dynamics [1]

Core Viewpoint - ST诺泰's subsidiary, Hangzhou Ausino Biotechnology Co., Ltd., has successfully passed the GMP compliance inspection for its active pharmaceutical ingredient, Aogtewei Sodium, marking a significant milestone in its production capabilities and quality management system [1] Group 1: Company Achievements - The company received the GMP compliance inspection notice from the Zhejiang Provincial Drug Administration, indicating its adherence to high production standards [1] - The successful inspection reinforces the company's commitment to "time-leading and technology-leading" operational philosophy [1] - The achievement is pivotal for the company's CDMO business, extending its value from high-level intermediates to active pharmaceutical ingredients [1] Group 2: Industry Implications - The compliance with GMP standards is expected to positively impact the company's ability to attract innovative pharmaceutical clients [1] - This milestone reflects the company's competitive edge in the pharmaceutical manufacturing sector, particularly in the production of innovative drug raw materials [1]

Core Viewpoint - The company *ST Jingfeng has received a civil ruling from the Intermediate People's Court of Changde City, Hunan Province, approving the reorganization plan and terminating the reorganization process [1] Group 1 - The court's decision is based on the approval of the reorganization plan for Hunan Jingfeng Pharmaceutical Co., Ltd [1] - The termination of the reorganization process indicates a significant development in the company's financial restructuring efforts [1]

Core Viewpoint - The A-share market is expected to enter a slow bull phase in 2025, with major indices significantly rising. As the annual report preview window approaches in early 2026, institutional investors are likely to focus on stocks with long-term growth potential and valuation revaluation space [2][3]. Group 1: Target Price Insights from Citic Securities - Citic Securities has identified 12 stocks with a target price increase of over 50%, indicating a recovery in market confidence. The focus is on sectors that can articulate a logical recovery narrative, particularly in consumer and real estate chains [2][3]. - Among the stocks covered, the highest target price increase is for Baili Tianheng, with a target price of 1322 CNY compared to a closing price of 269.69 CNY, representing a potential upside of 390.19% [3][4]. Group 2: Target Price Insights from Huatai Securities - Huatai Securities has identified 15 stocks with a target price increase of over 50%, focusing on sectors with sustainable recovery capabilities, particularly in price increase chains, high-end manufacturing, and AI [5][6]. - The highest target price increase is for Tianci Materials, with a target price of 80.5 CNY compared to a closing price of 40.04 CNY, indicating a potential upside of 101.05% [6]. Group 3: Target Price Insights from Guotai Junan - Guotai Junan has identified 13 stocks with a target price increase of over 50%, with China Railway leading at a target price of 9.07 CNY against a closing price of 5.37 CNY, representing a potential upside of 68.90% [8][9]. - The firm emphasizes the long-term potential of the "transformation bull" market, supported by improved regulatory governance and economic transformation [8]. Group 4: Target Price Insights from GF Securities - GF Securities has identified three stocks with significant target price increases, including Pudong Development Bank with a target price of 15.65 CNY compared to a closing price of 10.06 CNY, indicating a potential upside of 55.57% [10][11]. - The firm anticipates a strong seasonal market effect during the spring, particularly around the Chinese New Year [10]. Group 5: Target Price Insights from Guotai Securities - Guotai Securities has identified three stocks with target price increases over 50%, including Betta Pharmaceuticals with a target price of 71.95 CNY against a closing price of 45.70 CNY, representing a potential upside of 57.44% [13][15]. - The firm highlights the importance of technology and overseas expansion as key drivers for future growth [13]. Group 6: Target Price Insights from Dongwu Securities - Dongwu Securities has identified three stocks with the highest target price increases, including Tianci Materials with a target price of 79.20 CNY compared to a closing price of 40.40 CNY, indicating a potential upside of 97.80% [19][20]. - The firm expects a strong performance in the market as it transitions towards technology and cyclical sectors [19]. Group 7: Target Price Insights from Guojin Securities - Guojin Securities has identified China Pacific Insurance as the only stock with a target price increase over 50%, with a target price of 73.18 CNY against a closing price of 44.36 CNY, representing a potential upside of 64.97% [16][18]. - The firm believes that the insurance sector is entering a new cycle of growth driven by both volume and price increases [16].

*ST景峰公告，重整计划将以景峰医药现有股本8.8亿股为基数，按照每10股转增10股的比例实施资本公 积金转增股本，共计可转增8.8亿股股票。转增后，景峰医药总股本将增至17.6亿股。前述转增的8.8亿 股股票不再向原股东分配，全部用于引入重整投资人，并由重整投资人提供资金认购，相应资金用于根 据重整计划的规定支付破产费用、清偿各类债务、补充公司流动资金等。 ...

近日，广生堂发布公告称，预计2025年度归母净利润亏损约为1.7亿元至2.4亿元，扣除非经常性损益后的净利润预计 亏损约为1.77亿元至2.48亿元。 公告中提到，业绩亏损的主要原因包括持续的研发投入以及前期固定资产投资较大，导致研发费用和管理费用保持在 较高水平。此外，预计非经常性损益对公司归母净利润的影响约为750万元，同比减少约3573万元，主要因政府补助 大幅减少。 （广生堂公告） ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Insights - The approval of Lurcatinib cream marks a significant opportunity in the vitiligo market, being the first and only targeted therapy approved in China for this condition [7] - Clinical trials have shown positive results, with a significant percentage of patients achieving at least a 75% improvement in facial vitiligo area score after 24 weeks of treatment [7] - The company is also pursuing additional indications for Lurcatinib cream, including atopic dermatitis, which could further enhance its market potential [7] Financial Forecast and Valuation - Revenue projections for the company are as follows: 2023: 8,013 million RMB, 2024: 7,469 million RMB, 2025: 8,166 million RMB, 2026: 9,628 million RMB, and 2027: 12,069 million RMB, with growth rates of -12.4%, -6.8%, 9.3%, 17.9%, and 25.4% respectively [6] - Net profit forecasts are: 2023: 2,401 million RMB, 2024: 1,620 million RMB, 2025: 1,681 million RMB, 2026: 1,942 million RMB, and 2027: 2,333 million RMB, with growth rates of -26.3%, -32.5%, 3.8%, 15.6%, and 20.1% respectively [6] - The estimated reasonable market value for the company in 2026 is 677 billion HKD, based on a combination of price-to-earnings and price-to-sales ratios [7]